Clinical Perspective on p 174
Criteria for reporting a nonsynonymous variant as pathogenic in Mendelian disease has relied on several criteria (Table 1) , [2] [3] [4] including its novel identity. In earlier Mendelian studies, variants were attributed as novel based on their absence in approximately 200 to 400 unaffected chromo-somes 5 and more recently in larger numbers (usually 500 -1000). 6, 7 A current method for assessing the novelty of a variant has been to determine its presence or absence in dbSNP. However, regardless of approach used, the lack of large numbers of clinically defined and ethnically matched control samples has been a confounding factor for many analyses. Furthermore, although the recent rapid advances and application of next-generation sequencing has nearly doubled the amount of publicly available variant data in the past year alone, dbSNP is becoming increasingly "contaminated" with disease mutations that are not sufficiently annotated. Thus, variants determined as novel in earlier study designs may now be hidden in dbSNP among a pool of rare variants present in the general population, some of which may be benign and some pathogenic or deleterious.
Our own work in a rare variant Mendelian disease has focused on idiopathic dilated cardiomyopathy (DCM). DCM is geneti-cally heterogeneous, typically showing autosomal-dominant transmission with variable age of onset and reduced penetrance. 4 Rare variants in Ͼ30 previously reported DCM genes account for approximately 35% to 40% of familial cases, whereas the remaining genetic cause remains to be determined. 4 We have contributed 95 DCM variants to the literature, 8 -13 but unaffected individuals for these studies were limited. The Exome Sequencing project (ESP), funded by the National Heart, Lung and Blood Institute, recently released a searchable public database containing genetic variants identified in the human exome for Ͼ2400 individuals. Because exome sequencing is now commonly applied in discovery of rare variants in Mendelian disease, 14 we catalogued the 197 discrete variants from 235 DCM cases ( Supplemental Table I ) and screened for their presence in the exome sequences of 1351 European and 1088 African-descent individuals. Although most of these variants were not present in the ESP database, those that were present provide insight into preliminary guidance for future use of large publicly available genomic resources.
Methods

Data Collection
We collated single nucleotide substitutions or small insertion/ deletion allelic variants reported in the literature as "mutations" or "rare variants" in 30 autosomal DCM genes (LMNA, MYH6, MYPN,  TNNT2, SCN5A, MYBPC3, RBM20, TMPO, LAMA4, VCL, LDB3,  TCAP, PSEN1, PSEN2, ACTN2, CRYAB, TPM1, ABCC9, ACTC,  PDLIM3, ILK, TNNC1, TNNI3, PLN, DES, SGCD, CSRP3 , TTN, ANKRD1, BAG3) as previously published in a review 4 and subsequent publications. 8, 15 Genomic positions (Hg19) and the reference and alternate allele on the forward strand were determined for each variant. Conservation for single base variants and prediction of functional effects was assessed with PhastCons, 16 GERP, 17 and Grantham scores, 18 using SeattleSeq SNP annotation (http://snp.gs.washington.edu/ SeattleSeqAnnotation131/) and PolyPhen2. 19 
Search for Published DCM Variants in Exome Sequencing Project Data
Details of the ESP data set are described in supplemental methods. Exome sequencing was performed at the Broad Institute or the University of Washington. Single base variant data for these analyses are available on the ESP Exome Variant Server (http://evs.gs.washington.edu/EVS/). Genomic positions of DCM single base variants were searched against exome data for 2439 individuals, of which 1351 were of European and 1088 were of African descent, respectively. For small insertion deletions, genomic positions 15 bases either side of the reported variant were searched against VCF files for 1200 ESP controls of which 1028 were of European and 167 were of African descent and 5 were of unknown ancestry, respectively. Of 1200 ESP individuals, approximately 600 overlapped with those used for single base analysis.
Exome Sequencing of DCM Pedigree
The exomes of 3 related individuals with DCM were sequenced as previously described. 8
Statistical Analysis
Wilcoxon 2-sample tests to determine statistical difference of Grantham, PhastCon, and GERP scores between DCM variants present and absent in the ESP data set were performed in SAS Version 9.2.
Results
ESP Data Across DCM Genes and Variant Positions
Only 1 of 30 autosomal DCM genes, RBM20, was not captured in this version of the ESP data set, eliminating its 9 known DCM variants from consideration. 11, 20 The remaining 29 genes were included in the ESP target sequence with an average sequence coverage exceeding 60ϫ and with a minimum of Ͼ80% of the target sequence having coverage exceeding 20ϫ ( Supplemental Table II ).
DCM Allelic Variation
Allelic variants from 29 genes reported as either "mutations" or "rare variants" causative of DCM, and in 1 case as a "disease modifier," from 53 published studies are summarized ( Figure 1 ). A total of 235 DCM cases with variants attributed as causative of disease were reported, of which 197 variants were discrete. Of these 197, 87 were reported in our studies 8 -13 and 11 were reported by Ͼ1 study. Most variants (88%) were "private" to a single family with the remaining occurring in 2 to 4 DCM probands; 89% were single base substitutions (93% missense, 5% nonsense, and 2% occurring in consensus splice sites). The remaining 11% of variants were small insertion/deletions (indels) ranging from 1 to 4 bases in size, of which 86% resulted in frameshifts within the coding regions. Most variants (73.6%) occurred in familial dilated cardiomyopathy, 24.4% occurred in sporadic cases, and 2% were observed in both familial and sporadic DCM cases.
Known DCM Allelic Variants Present in dbSNP Build 131
Fifty-two of 176 single base substitution variants were present in dbSNP, of which 18 have no reported population frequency data, 20 have reported frequency of Ͻ0.1%, 2 have frequencies between 0.1% and 1%, and 7 have frequencies Ͼ1% in at least 1 population. Only 22 of 52 (42%) of known DCM variants present in dbSNP were tagged as "clinically associated." Eight of 21 small indels were also present in dbSNP and 7 of 8 were flagged as "clinically associated." Seven of 8 indels had no population frequency data and 1 (TNNT2 Lys210del) was not identified in 243 individuals from European, Asian, Hispanic, and Yoruban populations.
Known DCM Allelic Variants Present in >2000 ESP Exomes
A total of 31 single base substitutions (17.6%) reported in the literature as "mutations" or "rare variants," and in 1 case (LDB3 Lys204Arg) 21 as a "disease modifier," were also present in the ESP data set ( Table 2 ). These variants occurred in 17 of the 29 DCM genes captured in the ESP data set (Table 3 ). Frequencies in ESP individuals ranged from 0% to 0.59% in Europeans and from 0% to 4.64% in Africans. Two variants occurred at frequency Ͼ1% in ESP individuals of African ancestry: LDB3 Lys204Arg (4.64%) and LDB3 Asp117Asn (1.33%). These variants were highly conserved with PhastCons scores of 1 and 0.997 and GERP scores of 5.55 and 3.48, respectively, although Grantham scores for these variants were not suggestive of structural impact (26 and 23, respectively, in which a score Ͼ50 is suggestive of impact). Lys204Arg was predicted to be "prob-ably damaging" by PolyPhen2, whereas the discovery study observed this variant in 6 DNAs from black control individuals and suggested it was a disease modifier or polymorphism. 21 Asp117Asn was predicted to be benign by PolyPhen2, but despite these predictions, cells transfected with this particular variant showed cytoskeleton disarray. 21 Eighteen of 31 single base substitutions present in the ESP data set were also present in dbSNP (3 of which were flagged as clinically associated). Thirteen variants not present in dbSNP but present in ESP individuals had frequencies ranging from 0.04% to 1.33% in at least 1 population. Published functional data were available for 15 of these 31 variants with 13 of 15 showing some functional deficits, 12,21,28 -36 whereas 2 of 15 showed no significant functional effect. In the case of SCN5A Ile1835Thr, observed in the ESP individuals of African origin at a frequency of 0.54% (absent in those of European ancestry), sodium current was significantly altered but only in the presence of a constitutively expressed SCN5A transcript variant, Q1077del. 37 Among the 21 DCM indels, an in-frame deletion of a single amino acid (SGCD Lys238del) was detected in the ESP individuals, occurring in 6 of 134 chromosomes at this position (1.8%) from individuals of African descent but not present in any individuals of European descent. A second DCM indel was identified in a single heterozygous individual of European descent within the ESP data as insertion A at chr12: 21958185. The DCM variant at this locus was reported as a complex deletion of ATT and an insertion of AAAT resulting in a frameshift in ABCC9 with a functional deficit supported by cell-based assays showing an abnormal adenosine 5Ј-triphosphate-sensitive potassium channel phenotype 38 (chr12:21958186 -21958188).
Of the DCM variants present in ESP individuals, 5 were present only in samples of European origin, whereas none were unique to samples of black origin. This is likely a reflection of the initial DCM discovery samples, which were predominantly of European origin. The exact composition of the DCM discovery samples is not reported in several of the published manuscripts but for our own published cohort, 8 -13 which contributed 44% of variants in the study, patients are 93% European, 5% black, and 2% other origin.
Lack of Discriminating Features of DCM Variants Present Versus Those Absent in the ESP Data Set
For single base substitutions, we compared DCM variants present in the ESP data set against those that were absent (novel) under the assumption that DCM variants identified in the general population may be less conserved, and thus less pathogenic, than novel variants unique to DCM. However, conservation scores at the nucleotide (GERP) or amino acid level (PhastCons and Grantham scores) and PolyPhen2 classification did not discriminate between DCM variants present in the ESP data set and those that were absent. Of those present in the ESP data set, 7 were classed as "benign," 16 were classified as "probably damaging," and 8 as "possibly damaging." Wilcoxon 2-sample tests of Grantham and GERP scores for variants present in the ESP data set versus those that were novel were not significantly different with probability values of 0.26 and 0.20 (1-tailed), respectively. PhastCons scores between the 2 groups showed weak evidence for statistical difference (Pϭ0.049, 1-tailed; average 0.951) compared with 0.858 in DCM variants that were present in the ESP data set, although this was not significant after correction for multiple testing.
We further stratified those DCM variants present in the ESP against those that were novel by whether they occurred in familial or sporadic DCM cases and the amount of supporting functional data. Forty-four percent of DCM variants present in the ESP data set occurred in sporadic cases compared with 21% of the novel variants (Pϭ0.002; 2-tailed). One possibility for the excess of sporadic DCM cases with variants that were also observed in the ESP data set is that these variants were false-positives for disease causation. An alternate possibility is that these rare variants were low penetrance or susceptibility alleles that could be resolved to some extent by functional assays. Six of 15 variants present in both sporadic DCM cases and the ESP data set showed some functional deficit, suggesting that they were low penetrance alleles. Furthermore, no significant difference was observed between the amount of supporting functional data in those variants present and those that were absent in the ESP data (Pϭ0.43, 2-tailed).
The true picture may become clearer once functional assays are available for many more variants. Based on the assumption that DCM variants with functional data that have also been observed in the ESP data set are indeed pathogenic but with reduced penetrance, we propose an empirically derived frequency cutoff to aid in determining pathogenicity. In this data set, there were 14 DCM variants with supporting functional data that were also observed in the 2439 ESP individuals. In the ESP data set, the median frequency of these variants was 0.04% (2 of 4878 alleles), which we suggest may be a useful cut point for lower penetrance alleles when filtering exome data.
Application of a 0.04% Cut Point to Exome Sequencing Data in a Multiply Affected DCM Pedigree
To further illustrate the potential use of the ESP data set and evaluate our proposed cut point of allele frequency of 0.04%, we performed exome sequence analysis on 3 DCM cases within the same pedigree, known to be point mutation-negative for 16 known DCM genes, 8 -13 (Figure 2 ; Table 4 ). After filtering against dbSNP and 1000 Genomes Project, an average of 368 nonsynonymous or splice site variants remained per individual ( Table 4 ). We then screened the remaining variants against the ESP data and categorized these into 2 discrete categories: novel variants (absent from ESP data) and very rare variants (present 1 and 2 times in the ESP data set, a frequency of 0.04%). This reduced the number of novel variants to approximately 100 per individual, and sharing across first cousins, reduced this number to 18. Sharing across all 3 affected individuals reduced the number of novel variants to 8 genes (OTOP1, FSIP1, LOC100130086, FAM115C, CCL3L3, FRG1, CDC27, and EPB41L3). Ten additional rare variants were shared between first cousins that also occurred between 1 and 2 times in the ESP data, and this was reduced to 2 variants (COLQ at chr3:15507925 and OR11H12 at chr14:19378189) when sharing across all 3 affected members. On further examination of DCM transcriptome data, previously described, 8 only FRG1, EPB41L3, and COLQ were expressed in heart tissue. FRG1 (Facioscapulohumeral muscular dystrophy Region Gene 1) is a valid candidate, given that other DCM genes such as DMD1, LMNA, and BAG3 are also causative of muscular dystrophy. 39, 40 However, this variant resulted from paralagous sequence (unpublished data). The remaining variants occurred in EPB41L3, The no. of variants per DCM gene that also occurred in the ESP data set is shown with the highest allele frequency and highest no. of observations in a single ESP population. Where Ͼ1 variant per gene is observed in the ESP population, the range of frequency and occurrence is shown. DCM indicates dilated cardiomyopathy; ESP, Exome Sequencing Project; NA, not applicable.
*RBM20 was not captured in the ESP data set but is included here to demonstrate its frequency in the DCM in context to other known genes. Table 3 and reflect the variants in common between these combinations of patients. Relationships are AB, first cousins; BC, aunt/niece; and AC are first cousin/first cousin once removed.
(erythrocyte protein band 4.1) and COLQ (collagenic tail of endplate acetylcholinesterase), the former being a novel variant (chr18:5423409 TϾC) and the latter (chr3:15507925 CϾG) occurring in 2/2702 ESP alleles of European ancestry and in 0/2174 ESP alleles of African ancestry. On the basis of our findings with known DCM variants occurring at very low frequency in the ESP data set, we consider COLQ to be an equally valid candidate as EPB41L3. Further investigation is underway.
Discussion
Exome sequencing is a recently developed approach with the potential to uncover pathogenic mutations for Mendelian diseases. 14 Because of its comprehensive nature, the ESP exome data set (ESP2500) provides a new coding reference database (http://evs.gs.washington.edu/EVS/). Using this resource, we analyzed DCM, a rare variant Mendelian adult-onset disease, for the number of reported DCM variants present among the ESP data set and dbSNP. Our results raise several issues.
A filtering approach based on removing variants found in exome data from unaffected individuals and variants in the dbSNP/1000 Genomes Project has proved effective in many Mendelian diseases, 14 but these likely represent extremely rare diseases from highly penetrant mutations. When this approach is applied to other disease models with variable penetrance and very rare allele frequency (0.1%), it will likely be less effective in discerning causative alleles. The development of nextgeneration sequencing technology has rapidly increased the amount of publicly available sequence variant data. As we report here for DCM, 16.8% of variants previously reported as disease causative are present in the sequenced individuals within the 2439 ESP samples. It is possible that a fraction of these rare variants were false-positives, although the supporting functional data suggested they may actually be lower penetrance diseasecausing alleles. Importantly, prior to large-scale data sets such as the ESP, it has been nearly impossible to accurately assess the level of penetrance due to the lack of large population-based estimates of variant allele frequencies relative to their disease frequencies.
This raises a second issue: how to distinguish pathogenic variants present at very low frequency in the general population from benign rare variants. Understandably, an oversimplified filtering approach could result in discarding variants that are truly pathogenic. Fourteen of the 33 (42%) DCM variants that were also present in ESP individuals had functional effects in either heterologous cell-based assays or in animal models. In an effort to derive guidance from this previously published data, we suggest an allele frequency of 0.04% as a conservative initial cut point, which is the median allele frequency of variants present in the ESP but also with supporting functional data. In our own example of exome sequencing of a DCM pedigree (Table 4) , this analysis yielded an additional candidate gene.
Ideally, functional assays would be performed for all variants, because the use of any cut point has caveats. CSRP3 Trp4Arg is a pertinent example, as it has been observed in multiple DCM families from independent studies, 10, 31, 32 and was observed within the ESP individuals at a frequency of 0.35% in individuals of European and 0.05% in individuals of African descent, respectively. The CSRP3 Trp4Arg variant specifically affects the ability of Csrp3 to interact with T-cap 41 and in a knock-in mouse model resulted in an age-and gene dosage-dependent hypertrophic cardiomyopathy and heart failure phenotype. 31 Further discussion is deserved for the SCN5A variant, Ile1835Thr, also present in dbSNP (rs45563942) with no clinical association. This variant was observed at a frequency of 0.54% (7 of 1292 alleles) in the ESP individuals of African ancestry and absent in those of European origin. In a cell-based assay, Ile1835Thr significantly reduced peak sodium current, but the effect was dependent on genetic background in the context of transcriptional variation and a combination with a common polymorphism, SCN5A H558R (rs1805124). 37 Two constitutively expressed SCN5A transcript variants (not allelic variants) exist at frequencies of 65% and 35% expression in heart. 42 These transcripts are identical with the exception that the more highly expressed transcript has a deletion of a single amino acid, Q1077. The functional change in sodium current due to the rare DCM variant, Ile1835Thr, was specifically observed in cDNA constructs for the Q1077deletion transcript in combination with the common H558R variant and no significant change was observed on the Q1077 background.
These levels of complexity are likely just 1 example of genetic interactions, and DCM is but 1 paradigm that the ESP data can illuminate. Supporting evidence for our preliminary cut point is derived from the example of the long-QT syndrome. Although like with DCM, inheritance is predominantly autosomal-dominant, a study of 147 discrete variants from 2 long-QT syndrome genes in 753 families suggested that long-QT alleles are more frequently transmitted to daughters than to sons. 43 In this example, careful matching of unaffected individuals by gender could also be important. However, only 1 variant, KCNQ1 Pro320His, is present in the ESP data set, with a frequency of 0.037% in individuals of European origin, falling within our suggested cut point. Traditionally, Mendelian disease has been viewed as caused by 1 unique or very rare variant in an individual or pedigree. However, this is likely an oversimplification, because other genetic disease paradigms are possible. 44 We note that DCM has been shown to result principally from autosomal-dominant transmission, commonly understood to result in gain of function mutations, although loss of function, at least for calcium handling contractile proteins in DCM, also commonly occurs. 45 Much greater understanding of disease mechanisms may be relevant, including the possibility of other more complex genetic mechanisms such as di-or multigenic "recessive" mechanisms where multiple dysfunctional protein cascades interact, all of which leads to the final phenotype of DCM. 44
Limitations
Use of unaffected individuals from the same ethnicity and geographical region is highly important. The ESP data set consists of European and black ancestries, and a small proportion of the DCM cases are of other origins. This is a potential bias in our study, most strongly highlighted by the failure to observe the LMNA Leu85Arg variant in the ESP data. This variant is present in dbSNP and has a reported frequency Ͼ1% in Asian and sub-Saharan Africans and Ͼ20% in Maasai.
Our proposed allele frequency cut point of 0.04% is the median of a small number of observations, and thus with larger sample sizes and more functional data will likely need to be revised. This is the first empirical evidence derived from an exome data set that provides any guidance, although it may differ for other phenotypes.
Conclusions
In the exome era, traditional boundaries between Mendelian and more complex diseases will be tested, as illustrated in this example of DCM. This will contribute a degree of uncertainty in clinical interpretation of Mendelian gene variants. The importance of careful annotation of variants cannot be underestimated and through this, we predict the level of evidence to assign pathogenicity will be enhanced.
